Current status of dendritic cell immunotherapy of malignancies.
Publication
, Journal Article
Mosca, PJ; Clay, TM; Kim Lyerly, H; Morse, MA
Published in: Int Rev Immunol
2003
Because dendritic cells (DC) are central to the induction of antigen-specific T cell responses, their use for the active immunotherapy of malignancies has been of considerable interest. Since clinical trials with DC-based vaccines have been initiated, a number of important developmental issues have become apparent. These include the ideal source and type of DC, the form of antigen and method of loading DC, whether to induce maturation, the route and timing of immunization, and the optimal clinical scenario. Clinical responses such as stability of disease and tumor regressions have been reported in some patients, particularly with melanoma, myeloma, and prostate cancer.
Duke Scholars
Published In
Int Rev Immunol
DOI
ISSN
0883-0185
Publication Date
2003
Volume
22
Issue
3-4
Start / End Page
255 / 281
Location
England
Related Subject Headings
- Neoplasms
- Immunotherapy
- Immunology
- Humans
- Genetic Vectors
- Dendritic Cells
- Clinical Trials as Topic
- 3204 Immunology
- 1107 Immunology
Citation
APA
Chicago
ICMJE
MLA
NLM
Mosca, P. J., Clay, T. M., Kim Lyerly, H., & Morse, M. A. (2003). Current status of dendritic cell immunotherapy of malignancies. Int Rev Immunol, 22(3–4), 255–281. https://doi.org/10.1080/08830180305223
Mosca, Paul J., Timothy M. Clay, H. Kim Lyerly, and Michael A. Morse. “Current status of dendritic cell immunotherapy of malignancies.” Int Rev Immunol 22, no. 3–4 (2003): 255–81. https://doi.org/10.1080/08830180305223.
Mosca PJ, Clay TM, Kim Lyerly H, Morse MA. Current status of dendritic cell immunotherapy of malignancies. Int Rev Immunol. 2003;22(3–4):255–81.
Mosca, Paul J., et al. “Current status of dendritic cell immunotherapy of malignancies.” Int Rev Immunol, vol. 22, no. 3–4, 2003, pp. 255–81. Pubmed, doi:10.1080/08830180305223.
Mosca PJ, Clay TM, Kim Lyerly H, Morse MA. Current status of dendritic cell immunotherapy of malignancies. Int Rev Immunol. 2003;22(3–4):255–281.
Published In
Int Rev Immunol
DOI
ISSN
0883-0185
Publication Date
2003
Volume
22
Issue
3-4
Start / End Page
255 / 281
Location
England
Related Subject Headings
- Neoplasms
- Immunotherapy
- Immunology
- Humans
- Genetic Vectors
- Dendritic Cells
- Clinical Trials as Topic
- 3204 Immunology
- 1107 Immunology